Eric Lefkofsky is Working for a Cure for Cancer

It’s rare for entrepreneurs to turn their attention to medicine, but Eric Lefkofsky is doing it. He made is fortune by starting companies that merge technology and finance, such as Groupon, Mediaocean, and Uptake Technologies. He insists that he dislikes the pressure that comes with starting a new company, but that hasn’t stopped him from excelling at it.

Eric also directs his money and skills towards philanthropy in his home, Chicago. He supports the Art Institute of Chicago, the Steppenwolf Theatre Company, and he even works as an adjunct professor at the University of Chicago. He’s dedicated to improving both businesses and the world, and his latest project combines both of those passions.

That project is a company called Tempus, which uses data-driven technology and machine learning to help fight cancer. Eric founded Tempus with support from Keywell in 2015, after his wife was diagnosed with cancer. He believes that Tempus has the potential to revolutionize medicine in the same way that Google revolutionized the Internet, simply by making it possible to use a huge amount of data to guide treatments and what Eric knows.

Tempus isn’t the only company that is trying to bring about that kind of change, but it does have one significant advantage of the rest. Most of the companies rely on external funding, but Eric has chosen to fund Tempus from his own fortune to make sure that it gets everything that it needs. That allows it to stay lean and focus all of its efforts into making progress, instead of spending time and money on marketing or trying to find more funds.

There is still a lot of work to be done, but Tempus is already making progress. The company is already working on a clinical library and a system to make it easy for doctors to make sense of the data. It is doing so through a system of partnerships with medical groups that send patients to Tempus to provide data to the library in return for access to that library. It’s a complex mix of medicine and technology, but it has the potential to do a great deal of good for patients and more information click here.

More visit: www.forbes.com/profile/eric-lefkofsky